Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells
Matti L. Gild(Memorial Sloan Kettering Cancer Center), James A. Fagin(Memorial Sloan Kettering Cancer Center)
Cited by 66
Related Papers
High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.
|Journal of Clinical Investigation|1993|653
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
|Endocrine Related Cancer|2014|439
Genetic and Pharmacological Targeting of CSF-1/CSF-1R Inhibits Tumor-Associated Macrophages and Impairs BRAF-Induced Thyroid Cancer Progression
|PLoS ONE|2013|135
BRAFV600E Mutation Is Associated with Preferential Sensitivity to Mitogen-Activated Protein Kinase Kinase Inhibition in Thyroid Cancer Cell Lines
|The Journal of Clinical Endocrinology & Metabolism|2008|124
Transposon mutagenesis identifies chromatin modifiers cooperating with <i>Ras</i> in thyroid tumorigenesis and detects <i>ATXN7</i> as a cancer gene
|Proceedings of the National Academy of Sciences|2017|25